CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway

References

• Cristea CG, Gheonea IA, Săndulescu LD, et al. Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma. J Med Life. 2015;8(2):120–128.
   PubMedGoogle Scholar
• Shimada S, Mogushi K, Akiyama Y, et al. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine. 2019;40:457–470.
   PubMed Web of Science ®Google Scholar
• Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63(1):173–184.
   PubMed Web of Science ®Google Scholar
• Cha C, Dematteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol. 2005;19(1):25–37.
   PubMed Web of Science ®Google Scholar
• Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis. 2005;25(2):212–225.
   PubMed Web of Science ®Google Scholar
• Augsten M, Sjöberg E, Frings O, et al. Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties. Cancer Res. 2014;74(11):2999–3010.
   PubMed Web of Science ®Google Scholar
• Lu J, Chatterjee M, Schmid H, et al. CXCL14 as an emerging immune and inflammatory modulator. J Inflamm (Lond). 2016;13:1.
   PubMed Web of Science ®Google Scholar
• Hata R-I, Izukuri K, Kato Y, et al. Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice. Sci Rep. 2015;5:9083.
   PubMed Web of Science ®Google Scholar
• Nakayama R, Arikawa K, Bhawal UK. The epigenetic regulation of CXCL14 plays a role in the pathobiology of oral cancers. J Cancer. 2017;8(15):3014–3027.
   PubMed Web of Science ®Google Scholar
• Kleer CG, Bloushtain-Qimron N, Chen Y-H, et al. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res. 2008;14(17):5357–5367.
   PubMed Web of Science ®Google Scholar
• Zeng J, Yang X, Cheng L, et al. Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med. 2013;11(1):6.
   PubMedGoogle Scholar
• Wente MN, Mayer C, Gaida MM, et al. CXCL14 expression and potential function in pancreatic cancer. Cancer Lett. 2008;259(2):209–217.
   PubMed Web of Science ®Google Scholar
• Sjöberg E, Augsten M, Bergh J, et al. Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. Br J Cancer. 2016;114(10):1117–1124.
   PubMed Web of Science ®Google Scholar
• Wang W, Huang P, Zhang L, et al. Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci. 2013;104(11):1523–1531.
   PubMed Web of Science ®Google Scholar
• Gu X, Wang H, Wang A, et al. An intronic polymorphism rs2237062 in the CXCL14 gene influences HBV-related HCC progression in Chinese population. Mol Biol Rep. 2012;39(2):797–803.
   PubMed Web of Science ®Google Scholar
• Dobbin ZC, Landen CN. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013;14(4):8213–8227.
   PubMed Web of Science ®Google Scholar
• Jung MJ, Rho JK, Kim YM, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene. 2013;32(2):209–221.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu S, Chua M-S, et al. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway. Cell Death Dis. 2019;10(8):612.
   PubMedGoogle Scholar
• Wen W, Han T, Chen C, et al. Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling. Mol Cancer Ther. 2013;12(9):1796–1804.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, Calif). 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Lin F, Lin P, Zhao D, et al. Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif. 2012;45(3):207–216.
   PubMed Web of Science ®Google Scholar
• Alqahtani A, Khan Z, Alloghbi A, et al. Hepatocellular carcinoma: molecular mechanisms and targeted therapies. Medicina (Kaunas). 2019;55(9):526.
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–548.
   PubMed Web of Science ®Google Scholar
• Ji X, Shen Z, Zhao B, et al. CXCL14 and NOS1 expression in specimens from patients with stage I-IIIA nonsmall cell lung cancer after curative resection. Medicine (Baltimore). 2018;97(10):e0101.
   PubMed Web of Science ®Google Scholar
• Ikoma T, Ozawa S, Suzuki K, et al. Calcium-calmodulin signaling induced by epithelial cell differentiation upregulates BRAK/CXCL14 expression via the binding of SP1 to the BRAK promoter region. Biochem Biophys Res Commun. 2012;420(2):217–222.
   PubMed Web of Science ®Google Scholar
• Fazi B, Proserpio C, Galardi S, et al. The expression of the chemokine CXCL14 correlates with several aggressive aspects of glioblastoma and promotes key properties of glioblastoma cells. Int J Mol Sci. 2019;20(10):2496.
   Web of Science ®Google Scholar
• Zeng A, Yin J, Wang Z, et al. miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas. Oncoimmunology. 2018;7(12):e1510277.
   PubMed Web of Science ®Google Scholar
• Niu J, Lin Y, Liu P, et al. Microarray analysis on the lncRNA expression profile in male hepatocelluar carcinoma patients with chronic hepatitis B virus infection. Oncotarget. 2016;7(46):76169–76180.
   PubMedGoogle Scholar
• Lee HJ, Lee E-K, Seo YE, et al. Roles of Bcl-2 and caspase-9 and -3 in CD30-induced human eosinophil apoptosis. J Microbiol Immunol Infect = Wei Mian yu Gan Ran za Zhi. 2017;50(2):145–152.
   PubMed Web of Science ®Google Scholar
• Sari LM, Subita GP, Auerkari EI. Areca nut extract demonstrated apoptosis-inducing mechanism by increased caspase-3 activities on oral squamous cell carcinoma. F1000Res. 2018;7:723.
   PubMedGoogle Scholar
• Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book. 2013. DOI:10.1200/EdBook_AM.2013.33.e395.
   PubMedGoogle Scholar
• Minna E, Romeo P, Dugo M, et al. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. Oncotarget. 2016;7(11):12731–12747.
   PubMedGoogle Scholar
• Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 2010;321(1):20–28.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ge C, Zhao F, et al. NRBP2 overexpression increases the chemosensitivity of hepatocellular carcinoma cells via Akt signaling. Cancer Res. 2016;76(23):7059–7071.
   PubMed Web of Science ®Google Scholar
• Meng D, Frank AR, Jewell JL. mTOR signaling in stem and progenitor cells. Development. 2018;145(1):dev152595.
   PubMed Web of Science ®Google Scholar
• Tan FH, Bai Y, Saintigny P, et al. mTOR signalling in head and neck cancer: heads up. Cells. 2019;8(4):333.
   Web of Science ®Google Scholar
• Zhang Z, Zhu J, Huang Y, et al. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. Diagn Pathol. 2018;13(1):85.
   PubMedGoogle Scholar